Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 14, 2011Lara D. VeekenOpen Access

Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome

View Full Paper
Ask AI
Bookmark
Share

Authors

XBXenofon BaraliakosRheumazentrum RuhrgebietJLJoachim ListingUniversity of CopenhagenCFC. Fritz

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Baraliakos et al. (2011) studied this question.

synapsesocial.com/papers/6a8a4a0bf8670bac6e336d36https://doi.org/10.1093/rheumatology/ker194
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors1998 · 921 citations
  2. 2Studying patients with inflammatory back pain and arthritis of the lower limbs clinically and by magnetic resonance imaging: many, but not all patients with sacroiliitis have spondyloarthropathy1999 · 101 citations
  3. 3The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade(R))2004 · 112 citations
  4. 4Functional disability predicts total costs in patients with ankylosing spondylitis2002 · 145 citations
  5. 5Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab2005 · 260 citations